LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Wins First-Line FDA Approval for Jaypirca in CLL/SLL
The U.S. Food and Drug Administration (FDA) expanded approval of Eli Lilly’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with chronic...
Lilly Says Foundayo May Cut Modeled 10-Year Diabetes Risk by 57%
Eli Lilly said post-hoc analyses of its ATTAIN-1 trial found that its oral GLP-1 drug Foundayo (orforglipron) was associated with lower predicted long-term...
Eli Lilly Reports 20.8% Weight Loss With Retatrutide in Phase 3 Trial
Eli Lilly reported detailed results from its TRIUMPH-2 Phase 3 trial of investigational retatrutide in adults with type 2 diabetes and obesity. The results...
Eli Lilly's EloraTZP Delivers 23.3% Weight Loss in Phase 2b Trial
Eli Lilly reported positive results from a Phase 2b trial of EloraTZP, an investigational combination of eloralintide and tirzepatide. The trial enrolled 367...
Lilly Finds Zepbound Linked to More Weight Loss Than High-Dose Wegovy
Eli Lilly (LLY) reported results from an indirect treatment comparison suggesting its weight-loss drug Zepbound was associated with greater weight loss than...
Eli Lilly Says Foundayo Outperformed Novo's Oral Semaglutide in Indirect Comparison
Eli Lilly announced new data suggesting its oral GLP-1 drug Foundayo (orforglipron) provided greater weight loss and blood sugar control than Novo Nordisk's...
Eli Lilly Seeks Bigger Deals, Fueled by GLP-1 Cash Flow
Eli Lilly CEO David Ricks said the company is pursuing larger acquisitions to support future growth. In an interview with Bloomberg, he said future deals could...
🟢 Eli Lilly is trading 3.06% up today after FDA approval of once-weekly Onswik insulin
Eli Lilly is trading 3.06% up at $1,186.24 after FDA approval of Onswik, its once-weekly basal insulin for adults with type 2 diabetes. - Onswik offers an...
Home Depot Co-Founder Ken Langone Predicts Eli Lilly's Stock Could Reach $2,000
Ken Langone, Home Depot co-founder, expressed a highly optimistic outlook for Eli Lilly. He suggested the stock could reach $2,000 per share within three to...
Eli Lilly Captures 70% of New Senior Obesity Drug Market Following Medicare Coverage
Eli Lilly CEO Dave Ricks announced that 700,000 seniors have started GLP-1 obesity treatments since Medicare began covering the drugs in July 2026. The company...
Eli Lilly breaks ground on $6.5B Texas plant for weight-loss drugs
Eli Lilly and Company officially broke ground on a $6.5 billion manufacturing campus at Generation Park in Houston, Texas. The project represents the largest...
Eli Lilly traded tariff protection for higher overseas prices in secret deals
A Washington Post investigation revealed secret drug-pricing deals between the Trump administration and Eli Lilly. The agreements reportedly offered Eli Lilly...
Eli Lilly Wins FDA Approval for Breast Cancer Combo, Doubling Survival Results
The U.S. Food and Drug Administration (FDA) granted full approval for Eli Lilly’s Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib). This...
Eli Lilly taps QurCan for brain-penetrating drugs, targeting nervous system diseases
Eli Lilly and Company partnered with Canadian biotech QurCan Therapeutics to develop genetic medicines for the central and peripheral nervous systems. The...
Eli Lilly unveils retatrutide data, reporting 20.8% weight loss in diabetes trial
Eli Lilly and Company will present new cardiometabolic data at the European Association for the Study of Diabetes (EASD) 2026 meeting. The presentations...
🟢 Eli Lilly is trading 3.08% up today ahead of Morgan Stanley conference
Eli Lilly is trading 3.08% up now at $1150.03 as investors focus on the Morgan Stanley Global Healthcare Conference scheduled for September 14, 2026. - The...
Eli Lilly’s Foundayo Prescriptions Rise 8%, Narrowing Gap with Novo Nordisk
Eli Lilly’s oral weight-loss drug, Foundayo, saw total prescriptions climb nearly 8%. Total prescriptions for the drug reached approximately 47,500. Novo...
Eli Lilly commits $25B to deals, diversifying beyond obesity drugs
Eli Lilly CEO David Ricks outlined a strategy to secure growth into the 2030s during a CNBC interview. The company committed over $25 billion to more than 12...
Lilly's Zepbound and Taltz Combo Shows Sustained Efficacy in Psoriatic Disease
Eli Lilly announced positive 52-week results from two Phase 3b trials. The trials showed its weight-loss drug Zepbound, combined with arthritis treatment...
Eli Lilly buys Merida for $2.88B, leveraging obesity profits for autoimmune growth
Eli Lilly entered a definitive agreement to acquire Merida Biosciences for up to $2.88 billion. The deal includes an upfront cash payment plus additional...